Skip to main content

INVO Fertility, Inc.

For the period ended Mar 31, 2026. Filed Jun 22, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Jun 22, 2026

IVF$2.14+5.4%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31,2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________

Commission File Number:001-39701

INVO Fertility, Inc.

(Exact Name of Registrant as Specified in its Charter)

Nevada20-4036208
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
5582 Broadcast Court
Sarasota, FL34240
(Address of principal executive offices)(Zip Code)

(978) 878-9505

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par value per shareIVFThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐Accelerated filer ☐
Non-accelerated filer ☒Smaller reporting company ☒Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No☒

As of June 22, 2026, the Registrant had 1,786,035 shares of common stock outstanding.

INVO FERTILITY, INC. FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2026

TABLE OF CONTENTS

Item · Page Number
PART I. FINANCIAL INFORMATION
1.Financial Statements (Unaudited):4
Consolidated Balance Sheet as of March 31, 2026 (Unaudited) and December 31, 20254
Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025 (Unaudited)5
Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2026 and 2025 (Unaudited)6
Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025 (Unaudited)7
Notes to the Consolidated Financial Statements8
2.Management’s Discussion and Analysis of Financial Condition and Results of Operations29
3.Quantitative and Qualitative Disclosures about Market Risks38
4.Controls and Procedures38
PART II. OTHER INFORMATION
1.Legal Proceedings39
1A.Risk Factors39
2.Unregistered Sales of Equity Securities and Use of Proceeds39
3.Defaults Upon Senior Securities39
4.Mine Safety Disclosure39
5.Other Information39
6.Exhibits40
Signatures41

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates, and projections about our company, are not guarantees of future results or performance, and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the following:

●Our financial condition and need for additional capital;
●Our limited operating history and a history of net operating losses, and we depend on continued access to capital and clinic revenue growth to fund our operations;
●The competitiveness of the fertility and ART services industry;
●The dependence of our growth strategy on identifying and successfully completing and integrating fertility clinic acquisition;
●Our dependence on key executives, physicians, embryologists, and clinical personnel;
●Risks associated with operating certain of our fertility clinics as joint ventures;
●Reliance on a single third-party manufacturer for INVOcell production;
●Intellectual property risks;
●Evolving state and federal laws on abortion and embryo personhood;
●Federal and state regulation as both a fertility clinic operator and a medical device manufacturer;
●The FDA clearance process for the INVOcell and any future device modifications;
●Payor consolidation and managed care trends;
●Cybersecurity threats or data breaches involving sensitive patient health information;
●Material weaknesses in our internal control over financial reporting;
●Risks related to our common stock and capital structure; and
●Risks related to market and macroeconomic conditions.

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates, or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes, or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

This Quarterly Report on Form 10-Q may include market data and certain industry data and forecasts, which we may obtain from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies, and industry publications, articles, and surveys. Industry surveys, publications, consultant surveys, and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third-party sources.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.